/C O R R E C T I O N -- Privo Technologies/
PR Newswire —
In the news release, Privo Technologies Announces Milestone in PRV211 Arm of CLN-004 Clinical Trial: Primary Endpoint Met; No Serious Adverse Events Reported, issued 23-Jan-2026 by Privo Technologies over PR Newswire, we are advised by the company that changes have been made. The...